Kim, W. Seog., Shortt, J., Zinzani, P. L., Mikhailova, N., Radeski, D., Ribrag, V., Domingo Domenech, E., Sawas, A., Alexis, K., Emig, M., Elbadri, R., Hajela, P., Ravenstijn, P., Pinto, S., Garcia, L., Overesch, A., Pietzko, K., & Horwitz, S. (2024). A Phase 2 study of acimtamig (AFM13) in patients with CD30-positive, relapsed or refractory peripheral T-cell lymphomas. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-24-1913